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Background: Missing data are a common problem in prospective studies with a long follow-up, and the volume,
pattern and reasons for missing data may be relevant when estimating the cost of illness. We aimed to evaluate
the effects of different methods for dealing with missing longitudinal cost data and for costing caregiver time on
total societal costs in Alzheimer’s disease (AD).
Methods: GERAS is an 18-month observational study of costs associated with AD. Total societal costs included
patient health and social care costs, and caregiver health and informal care costs. Missing data were classified as
missing completely at random (MCAR), missing at random (MAR) or missing not at random (MNAR). Simulation
datasets were generated from baseline data with 10–40 % missing total cost data for each missing data mechanism.
Datasets were also simulated to reflect the missing cost data pattern at 18 months using MAR and MNAR assumptions.
Naïve and multiple imputation (MI) methods were applied to each dataset and results compared with complete GERAS
18-month cost data. Opportunity and replacement cost approaches were used for caregiver time, which was costed
with and without supervision included and with time for working caregivers only being costed.
Results: Total costs were available for 99.4 % of 1497 patients at baseline. For MCAR datasets, naïve methods performed
as well as MI methods. For MAR, MI methods performed better than naïve methods. All imputation approaches were
poor for MNAR data. For all approaches, percentage bias increased with missing data volume. For datasets reflecting
18-month patterns, a combination of imputation methods provided more accurate cost estimates (e.g. bias: −1 % vs −6 %
for single MI method), although different approaches to costing caregiver time had a greater impact on
estimated costs (29–43 % increase over base case estimate).
Conclusions: Methods used to impute missing cost data in AD will impact on accuracy of cost estimates
although varying approaches to costing informal caregiver time has the greatest impact on total costs.
Tailoring imputation methods to the reason for missing data will further our understanding of the best
analytical approach for studies involving cost outcomes.
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Many studies of people with Alzheimer’s disease (AD)
determine disease-related costs through cross-sectional
analysis or from retrospective databases. Such studies do
not account for missing cost data, which can lead to bias
and reduce the statistical power to detect effects [1, 2].
Also, they often assume that costs are missing com-
pletely at random (MCAR) or missing at random (MAR)
rather than missing not at random (MNAR); see Table 1
for a description of these missing data patterns [3]. Al-
though data can be missing for many reasons, dropout
of patients with AD dementia from longitudinal studies
is a known issue and may not occur completely at
random. About 20 % of patients drop out of a longitudinal
AD study each year [2] and, in the GERAS observational
study [4], 32.4 and 50.6 % of patients discontinued over 18
and 36 months, respectively (data on file). Such dropout
can be associated with various patient factors, including
poor cognitive performance or impaired functional ability
due to worsening disease status, comorbid medical illness,
as well as hospitalisation, institutionalisation or death
[2, 5]. Loss of the caregiver from the study due to death,
illness, increased burden or a change in caregiver will also
result in cost and resource use data not being collected.
The assumptions made when analysing cost data could
have a considerable influence on the conclusions being
made. It is, therefore, important to understand the limi-
tations of using a single imputation method for imputing
missing cost data (as explored by Oostenbrink &
Maiwenn [6]) compared with using different imputation
methods depending on the nature of the missingness. It
is also important to understand how these decisions
compare with other assumptions that are needed when
analysing cost data, including the assumptions re-
quired for calculating the costs of informal caregiver
time. Informal care costs are the largest component
of total societal costs associated with the care of
community-dwelling patients with AD [4, 7–10]. Various
methods are used to collect, categorise and assign a
monetary value to informal caregiver time [11–13], and
analytical methods such as capping caregiver hours to
allow for sleep, including time spent on supervision
and using different unit costs based on the working
status of the caregiver, can all affect estimates of in-
formal care costs [4, 10].Table 1 Patterns of missing data
Missing data pattern Description
Missing completely at random (MCAR) • Data are m
• Simple stat
Missing at random (MAR) • Probability
• MAR is the
Missing not at random (MNAR) • Missingnes
It is not possible to distinguish between MAR and MNAR based on observed dataThere is no consensus on the best method to use for
dealing with missing cost data and publications on cost
of illness studies usually do not provide information that
is relevant to understanding the possible impact of the
level of missing data and the methods used to deal with
it. For example, the analysis of missing data varied across
seven published longitudinal studies on the costs of
illness associated with AD or dementia that included
informal care time and a data collection period of at
least 6 months [7, 9, 14–18]. Most studies did not report
the amount of missing data, even though the choice of
method used to deal with such data may become more
important as the level of missing data increases. Several
of the studies did not describe how missing data were
managed in the cost analysis or whether any sensitivity
analyses were performed to examine the potential im-
pact of missing data assumptions on the results. Some
studies analysed only patients with complete cost data
[7], whereas others used some form of imputation method
based on assumptions around missingness, usually that
cost data are MAR [9, 14, 15, 17]. However, patients who
discontinue from studies due to institutionalisation or
death could be considered to have informative dropout
and, therefore, data could be defined as MNAR.
The first aim of the present analysis was to explore the
effectiveness of different imputation methods for dealing
with missing cost data from a prospective observational
study (the GERAS study [4]). Our second aim was to
compare the use of individual and combined methods of
imputing missing total societal cost data. Our third aim
was to compare the impact of imputation methods for
dealing with missing cost data with the impact of differ-
ent assumptions on the calculation of caregiver time.
Methods
GERAS study
GERAS is an 18-month prospective observational study
of costs associated with the care of community-dwelling
patients with AD dementia and their caregivers in three
European countries (France, Germany, UK) [4]. Full
details of the study design, patient characteristics and
baseline costs have been reported elsewhere [4]. Briefly,
the study enrolled community-dwelling patients aged at
least 55 years, meeting the National Institute of Neuro-
logical and Communicative Disorders and Stroke/issing for reasons not related to observed or unobserved variables
istical approaches to deal with missing data can provide unbiased results
of missingness is related to observed data but not to unobserved data
assumption for most imputation methods
s is related to unobserved data
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criteria for probable AD [19]), with a Mini-Mental State
Examination (MMSE) [20] score of ≤26, and presenting
within the normal course of care. Caregivers were infor-
mal carers who took responsibility for the day-to-day deci-
sions and provision of home care for the patients. Written
informed consent was obtained from all participants.
Health care resource use by patients and caregivers
was collected using the Resource Utilisation in Dementia
(RUD) instrument [21]. Caregiver informal care time
was recorded as time spent on basic activities of daily
living (ADL, e.g. bathing, feeding), instrumental ADL
(e.g. shopping, cooking) and supervision.
Cost data were calculated by country from the re-
source use information collected for the month before
the baseline visit. Monthly costs in Euros (2010 values)
were estimated by applying country-specific unit costs
for services and products used, with UK costs in pounds
sterling being converted to Euros as reported previously
[4]. Total societal costs were calculated by combining
patient health care costs (including hospitalisations,
outpatient visits and medication), patient social care
costs (including home care and day centre sessions),
caregiver health care costs, and caregiver informal care
costs (from time spent giving informal care), each of
which were calculated as reported previously [4]. Differ-
ent methods may be used for estimating informal care
time [11], and no one method has been established as
the preferred method. For this study, informal care costs
were calculated using the higher cost of either caregiver
time spent on the patient (excluding supervision time)
or caregiver missed work, with the same unit cost being
applied to both items. Different unit costs were applied
for working and non-working caregivers [4].
Design
The present analysis evaluated the performance of differ-
ent imputation methods for dealing with missing cost
data for patients with AD dementia through simulations
using actual cost data taken from the GERAS study. As
99.4 % of patients reported complete cost data at the
baseline assessment, there was a very low level of miss-
ing data. The simulations were constructed to look at
different patterns and volumes of missing total societal
cost data. We have not explored imputation at the cost
item level. The simulated datasets were generated using
baseline GERAS data where the ‘true’ (actual) cost esti-
mates were known, thus allowing the performance of
each imputation method in terms of mean costs and
standard errors (SEs) to be compared with known
GERAS cost data. As the purpose of this analysis was to
test the effectiveness of different methods for dealing
with missing cost data, there is no interpretation of the
cost data and we do not make any statements about therelationship between missing data and the factors used
to generate the simulated datasets.
Imputation methods
Oostenbrink & Maiwenn [6] compared a number of
different naïve and multiple imputation (MI) methods.
We explored a similar range of imputation methods to
see if Oostenbrink & Maiwenn’s conclusions were
supported when using these methods on actual cost data
rather than simulated cost data. We present the results
for one naïve method (complete case analysis) and one
MI method (MI Monte Carlo Markov Chain [MCMC]);
the other methods in general gave similar findings.
Among the so-called naïve methods for handling miss-
ing data [22], complete case analysis excludes the data
from all patients with missing data (i.e. no imputation)
and assumes that patients with complete data are repre-
sentative of those with missing data. However, as pa-
tients who do not complete their follow-up are often
those with more severe disease, complete case analysis
can be expected to underestimate costs. It can also ex-
clude a large proportion of the sample from the analysis.
Imputation methods replace a missing value that is
not observed with an estimated value [22]. Multiple im-
putation is an analytical approach that replaces each
missing value with a set of multiple (M > 1) simulated
values [6, 23, 24]. The creation of m sets of imputations
reflects uncertainty about the true values of the missing
data. After the MIs are created, m plausible versions of
the complete data exist. In this study, the results of the
m analysis are then combined to give one estimate of
mean costs.
MCMC algorithms are stochastic and converge to a
probability distribution [25]. In this case, the MCMC
method converges to the posterior predictive function
from which values are drawn to impute the data set. The
method assumes arbitrary missing data. In the present
analysis, a Jeffrey’s non-informative prior is used, with
multiple chains, a 2000 iteration burn-in, and 500 itera-
tions between imputations in a chain. Initial estimates
from the MCMC are from an expectation maximisation
algorithm. The MI MCMC method assumes that the
data are normally distributed.
Simulation datasets
A brief description of the theoretical generation of
missing cost data for the simulations is given below;
full details of how the simulation datasets were gener-
ated are provided in Additional file 1.
The simulation datasets were derived from the base-
line GERAS cost data; 1488 (99.4 %) of the 1497 patients
analysed had sufficient resource use information to
calculate costs [4]. Total societal costs were used for the
simulations and patient baseline characteristics from the
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tion datasets.
Algorithms were created to generate 12 different
simulation datasets with three different mechanisms
of missing cost data (MCAR, MAR and MNAR), each at
different volumes of missing total cost data (10, 20, 30 and
40 %), the potential range of missing data from longitudinal
studies of people with AD. In addition, two further simula-
tion datasets were generated (GERAS-1, GERAS-2), where
the pattern and volume of missing data reflected the
observed patient dropout rate during 18 months of follow-
up in the GERAS study.
MCAR datasets were created using a random number
generator to select patients to be missing and using
values that gave the required volume of missing data
(10–40 %).
MAR scenarios assume that some known factors pre-
dict which data are MAR. Our simulations were based
on a theoretical example of missing cost data being asso-
ciated with two baseline characteristics: patient func-
tional and cognitive status at baseline (i.e. Alzheimer’s
Disease Cooperative Study of Activities of Daily Living
Inventory, ADCS-ADL [26] and MMSE scores). Thus,
MAR datasets were generated by assigning missing cost
data based on a specific score for these two combined
variables, with the score being set to achieve the required
volume of missing data.
MNAR scenarios assume that some unknown factor(s)
cause the missing data. However, a factor must be used
to generate the theoretical MNAR dataset for the simu-
lations; we used baseline GERAS total cost data above a
specific value (which was set based on the volume of
missing data required for each dataset) to assign patients
as having missing costs.
In the real world, missing data comprise a mixture of
different patterns of missingness, with some patient data
being MCAR, and other data being MAR or MNAR. Be-
cause this was likely to be the case with the GERAS cost
data, we generated two simulation datasets, GERAS-1
and GERAS-2, to more closely represent the structure of
real missing data. First, we used the rate of patient dis-
continuation at the GERAS 18-month assessment and
the reasons for study discontinuation to give both a level
of missing cost data and different patterns of missing
cost data for specific groups of patients. Three different
reasons for missing data were defined: (1) missing due
to patient institutionalisation; (2) missing due to patient
death; and (3) missing because the patient had left the
study (i.e. lost to follow-up). The 18-month data from
GERAS showed that 15 % of patients were institutiona-
lised, 6 % had died, and 12 % were lost to follow-up,
which gave 33 % of missing cost data. Two simulation
datasets were then generated based on this missing data
pattern. In dataset GERAS-1, patients assigned as beinginstitutionalised were generated as MAR based on ob-
served data (e.g. MMSE and ADCS-ADL scores and care-
giver time), while in dataset GERAS-2, institutionalised
patients were assumed to be MNAR due to unobserved
data; these data were generated using total caregiver time
at baseline as the unknown factor (which was not used as
part of the imputation methods). In both GERAS-1 and
GERAS-2, patients assigned as being lost to follow-up
were assumed to be MCAR and were generated using a
random number generator, while death was generated as
MAR using a combination of observed factors (baseline
MMSE and ADCS-ADL scores, and patient age).Analyses
All analyses were carried out using SAS 9.2 (SAS Institute,
Cary, North Carolina, USA).
The simulation datasets generated for the 12 mecha-
nisms of missing data at different volumes of missing data
and the two patterns of real missing data (GERAS-1 and
GERAS-2) were each run against the two different imput-
ation methods described previously (complete cases, MI
MCMC). In addition, the impact of applying a combin-
ation of imputation methods to missing data was explored
using two different combination imputation scenarios for
the GERAS-1 and GERAS-2 datasets. In Combination
Scenario A, missing cost data for patients lost to follow-
up (assumed to be MCAR) were imputed using the naive
method of grouped means imputation, which uses the
mean costs from non-missing observations for each
MMSE severity group at baseline (mild, moderate; and
moderately severe/severe AD dementia based on MMSE
scores of 21–26, 15–20 and <15, respectively) to impute
missing data within each severity group; missing cost data
for patients institutionalised (assumed to be MAR) were
imputed using the MI MCMC method (including the fac-
tors MMSE score, ADCS-ADL score and caregiver time);
and missing cost data for patients who died (assumed to
be MAR) were imputed using the MI MCMC method
(including the factors patient age, MMSE score and
ADCS-ADL score). In Combination Scenario B, a fixed
cost (€2940 per month, cost of institutionalisation) was
used for missing cost data for institutionalised patients
(assumed to be MNAR); the imputation methods used for
missing cost data for patients who died or were lost to
follow-up were the same as for Combination Scenario A.
To avoid the results being influenced by one particular
set of data, we performed each imputation scenario 1000
times on slightly different sets of data generated by
random selection with replacement for each of the 14
simulation datasets generated. The estimates of these
costs from the 1000 iterations were combined and com-
pared with the ‘true’ cost estimates from the complete
sample with no missing cost data.
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performance of the imputation methods:
(1) mean costs (in Euros) for both the ‘true’ (actual)
mean cost from the complete sample and the
estimated mean cost from the imputed simulation
datasets;
(2) absolute and relative bias: calculated as the
difference in mean costs between the actual costs
for the GERAS complete sample dataset and the
estimated cost for the analysed sample; i.e. absolute
bias was calculated as (estimated cost−actual cost),
while relative bias (%) was calculated as [(estimated
−actual cost)/actual cost × 100]; these values should
be as close to zero as possible (negative values
indicate underestimation of costs, whereas positive
values reflect overestimation of costs);
(3) sampling standard error (SSE) for the estimator,
being the standard deviation (SD) of the mean
costs of the 1000 iterations;
(4) sampling average of the standard error estimator
(SEE), being the mean of the SEs of the 1000
iterations;
(5) ratio of SEE/SSE, which can be considered a
measure of whether the analysis provides an
adequate estimate of the SE of the dataset, and
reflects the extent to which the SEE approaches
the SSE (calculated as the ratio SEE/SSE);
(6) sampling coverage probability (CP) of the 95 %
confidence interval (CI), being the proportion of
iterations for which the 95 % CI includes the ‘true’
mean costs. If the CP is high, it means that the
estimated CI will generally include the ‘true’ mean
of the costs; a low CP indicates it is less likely to
contain the ‘true’ mean. Low CP scores are an
indication that the estimated mean is a poor
estimate of the ‘true’ mean.
For each analysis, the SSE can be considered as the
‘true’ SE and should be larger than the SE of the
complete sample to indicate the additional uncertainty
due to imputation of missing data.
Sensitivity analysis
Two sensitivity analyses were conducted to investigate the
impact of (1) using imputation methods that were
dependent on baseline characteristics, when unmeasured
confounders were present, and (2) the assumption of nor-
mality in smaller sample sizes. Further details of these sen-
sitivity analysis methods can be found in Additional file 2.
Alternative methods for costing caregiver time
To put the impact of using different imputation methods
for dealing with missing cost data into context, we assessedthe effects of using different methods to calculate informal
care costs on the estimate of total societal costs. In the base
case analysis, which was the same as the ‘true’ mean cost
used for the simulations, total societal costs were
calculated excluding caregiver supervision hours in the
opportunity cost approach. Alternative total societal cost
estimates were generated where: (1) caregiver supervision
time was included, (2) replacement costs were used instead
of opportunity costs, and (3) only caregiver time for work-
ing caregivers was included for caregiver informal costs
(i.e. caregiver time for non-working caregivers was not
costed; see Wimo et al. [4] for details).
Results
GERAS baseline data
Of the 1497 patients in the GERAS study analysed at
baseline, mean (SD) age was 77.6 (7.66) years, 54.8 %
were female, and the mean (95 % CI) MMSE score was
17.4 (17.1; 17.7) as reported previously [4].
Total societal costs were available for 1488 (99.4 %)
patients, with a mean monthly cost of €2101 (95 % CI:
€1980–2222).
Simulations
Figure 1 shows the % bias in mean costs for the two im-
putation methods (complete cases, MI MCMC) under the
different mechanisms and different volumes of missing
data. In general, the % bias increased as the volume of
missing data increased from 10 to 40 %. When data were
MCAR, the naïve imputation (complete cases) performed
as well as the more complicated MI MCMC method; for
complete cases, the rate of bias ranged from −0.03 % with
10 % missing data to 4 % with 40 % missing data; for MI
MCMC, the rate of bias ranged from 2 % with 10 % miss-
ing data to 15 % with 40 % missing data.
When data were MAR, the MI MCMC method
performed better at 10–30 % missing data (bias ranged
from −3 to 5 %) when compared with the complete case
analysis (bias ranged from −11 to –23 %). However, when
the level of missing data reached 40 %, the percent bias in
mean costs increased for the MI MCMC method (28 %),
and was of a similar magnitude to the complete cases
method (−29 %) although in the opposite direction.
When data were MNAR, all imputation methods
performed poorly and produced high levels of percent
bias in mean costs, showing an underestimation of costs:
complete cases bias ranged from −27 % at 10 % missing
data to −56 % at 40 % missing data; MI MCMC bias
ranged from −24 % at 10 % missing data to −50 % at
40 % missing data.
Table 2 summarises the results for the simulations for
the three different mechanisms of missing data for
complete cases and MI MCMC. For the MCAR and
MAR simulations, the SSE with the MI MCMC method
Fig. 1 Bias in mean costs for imputation methods for different mechanisms and levels of missing data. Abbreviations: MCAR: missing completely
at random; MAR: missing at random; MNAR: missing not at random; MCMC: Markov Chain Monte Carlo; MI: multiple imputation
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(reflecting greater variability) at all levels of missing data;
this was not seen for the complete cases method. For
the MNAR simulations, the SSE was lower than the SE
of the ‘true’ mean, whereas you would expect it to be
higher based on the uncertainty introduced with the
additional missing data. The results of the simulations
for the different mechanisms of missing data for all naïve
and MI methods examined are available on request.
Table 3 shows how the different imputation methods,
including both combination imputation scenarios, per-
formed when the cost data were generated based on the
actual level of missing cost data at the 18-month assess-
ment of the GERAS study [33 % missing data in total,
due to institutionalisation (15 %), death (6 %) and lost to
follow-up (12 %)]. For dataset GERAS-1, the MI MCMC
method performed as well as Combination Scenario A,
bias being −3 % for both methods. In comparison, the
complete cases method showed a higher level of bias
(−7 %). Although both the MI MCMC and Combination
Scenario A imputation methods gave good estimates of
the mean costs (i.e. −3 % bias) for the GERAS-1 dataset,
they underestimated the SE because the SEE/SSE ratios
were 0.64 and 0.66, respectively.
For dataset GERAS-2, the MI MCMC method per-
formed better than the complete cases method (Table 3).
A better approach was to use a combination of imput-
ation methods, especially Combination Scenario B,
which had a low level of bias (−1 %), even though it still
underestimated the SE (i.e. the SSE was 49, which was
lower than 61, the SE for the complete sample). Com-
bination Scenario B gave a lower bias (−1 %) than theMI MCMC method (−6 %), and the SEE/SSE ratio was
superior (0.86 for Combination Scenario B versus 0.53
for MI MCMC).
Sensitivity analyses
Findings from the sensitivity analyses using other naïve
methods and MI methods were consistent with the main
conclusions presented in this paper (see Additional file 2).
Cost estimates using alternative methods for costing
caregiver time
To put the assumptions around the different imputation
methods into context, cost estimates were calculated
using different assumptions on how to include caregiver
time into the estimate of total societal costs. The base
case scenario (where separate unit costs were used for
working and non-working caregivers and supervision
time was excluded in the opportunity cost approach),
mean monthly total societal costs for the whole cohort
were €2101 (95 % CI: €1980–2222). When supervision
time was included, mean monthly total societal costs
were €2995 (95 % CI: €2832–3158), representing a 43 %
increase from the base case estimate. When a single unit
cost was used for caregiver time (i.e. same unit cost for
working and non-working caregivers; supervision time
included), mean monthly total societal costs were €2707
(95 % CI: €2575–2839), corresponding to a 29 % increase
from the base case estimate. An alternative approach was
to not include costs of informal care when the caregiver is
not working for pay; in this analysis, mean monthly total
societal costs were €1597 (95 % CI: €1444–1749), giving a
−24 % difference from the base case estimate.
Table 2 Summary statistics of simulationsa with missing data patterns (MCAR, MAR, MNAR)
Imputation method for
missing data pattern
10 % missing 20 % missing 30 % Missing 40 % missing
Mean cost (€) Bias (%) SSE SEE CP Mean cost Bias (%) SSE SEE CP Mean cost Bias (%) SSE SEE CP Mean cost Bias (%) SSE SEE CP
Complete sample 2102 – 59 61 – – – 59 61 – – – 59 61 – – – 59 61 –
MCAR
Complete cases 2102 −0.7 (−0.03 %) 63 64 1.00 2121 18 (0.9 %) 68 69 1.00 2156 53 (3 %) 75 76 1.00 2181 79 (4 %) 87 87 0.99
MI MCMC 2150 48 (2 %) 68 58 1.00 2218 115 (5 %) 78 57 0.46 2300 198 (9 %) 93 57 0.03 2410 308 (15 %) 118 57 0.00
MAR
Complete cases 1871 −231 (−11 %) 56 57 0.00 1723 −379 (−18 %) 54 55 0.00 1624 −478 (−23 %) 59 59 0.00 1499 −603 (−29 %) 59 61 0.00
MI MCMC 2158 55 (3 %) 112 57 0.76 2039 −64 (−3 %) 83 48 0.65 2218 116 (5 %) 202 52 0.38 2683 581 (28 %) 417 69 0.09
MNAR
Complete cases 1544 −558 (−27 %) 27 28 0.00 1291 −812 (−39 %) 22 22 0.00 1096 −1007 (−48 %) 20 19 0.00 929 −1173 (−56 %) 17 16 0.00
MI MCMC 1602 −501 (−24 %) 28 26 0.00 1383 −720 (−34 %) 22 19 0.00 1212 −890 (−42 %) 20 15 0.00 1043 −1059 (−50 %) 19 11 0.00
% bias was calculated as (estimated−actual)/actual cost × 100), where actual cost was the mean cost for the complete sample
Abbreviations: CP coverage probability, MCMC Markov Chain Monte Carlo, MI multiple imputation, SEE standard error estimate, SSE sampling standard error
a1000 simulations and sample size 1497 for different levels of missing data (10–40 %)
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Table 3 Summary statistics of simulationsa with missing data pattern reflecting GERAS study data at 18 monthsb
GERAS-1c GERAS-2d
Imputation method Mean cost (€) Bias (%)e SSE SEE SEE/SSE CP Mean cost (€) Bias (%)e SSE SEE SEE/SSE CP
Complete sample 2101 – 64 62 0.97 – 2103 – 60 61 1.02 –
Naïve imputation method
Complete cases 1957 −144 (−7 %) 67 66 0.99 0.38 1689 −414 (−20 %) 52 54 1.04 0.00
Multiple imputation method
MI MCMC 2037 −64 (−3 %) 74 47 0.64 0.70 1969 −134 (−6 %) 77 41 0.53 0.22
Combination of imputation methods
Combination Scenario Af 2044 −57 (−3 %) 71 47 0.66 0.73 1947 −157 (−7 %) 69 41 0.59 0.12
Combination Scenario Bg 2296 195 (9 %) 62 49 0.79 0.02 2075 −28 (−1 %) 49 42 0.86 0.87
Numbers in bold text show the imputation method(s) that perform the best (lowest bias) for each of the two datasets (GERAS-1 and GERAS-2)
Abbreviations: CP coverage probability, MAR missing at random, MCAR missing completely at random, MCMC Markov Chain Monte Carlo, MI multiple imputation,
MNAR missing not at random, SEE standard error estimate, SSE sampling standard error
a1000 simulations and sample size 1497
bData missing for 33 % patients at 18 months: 15 % patients institutionalised, 6 % died, 12 % lost to follow-up
cGERAS-1: assumed patients institutionalised were based on a predictive equation (i.e. data MAR)
dGERAS-2: assumed patients institutionalised if their caregiver time was >470 h/month (i.e. data MNAR)
e% bias was calculated as ((estimated−actual)/actual cost × 100), where actual cost was the mean cost for the complete sample
fCombination Scenario A: patients lost to follow-up (data MCAR) had costs imputed using group means method, patients institutionalised (data MAR) were imputed
using MI MCMC method (including factors MMSE, ADCS-ADL and caregiver time), and patients who died (data MAR) had costs imputed using the MI MCMC method
(including factors MMSE, patient age and ADCS-ADL)
gCombination Scenario B: same imputation methods as Combination Scenario A, but a fixed cost (€2940 per month) was used for patients who were
institutionalised (data MNAR)
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Given that the volume of missing data and the methods
used to deal with missing data have been poorly reported
in previous cost studies in AD, our results showed the
importance of being able to understand the reasons for
missing data from prospective studies (including why
patients discontinue from studies) and how gathering
informative data about study discontinuation can lead to
better tailoring of methods for applying costs. Further-
more, we put these findings into context and demon-
strated that the method of quantification and costing of
informal caregiver time has the biggest impact on cost
estimates, way above that of the different methods for
handling missing data.
Having a nearly complete set of baseline cost data for
the large patient sample in the GERAS study allowed us
to simulate costs based on real-life data, which have
much greater variability and distribution than purely
theoretical data. Also, it allowed us to compare the
simulated costs with the ‘true’ costs used to simulate the
missing data, thereby providing a measure of the per-
formance (bias, accuracy and coverage) of the different
imputation methods. Our findings, therefore, extend pre-
vious analyses of missing cost data based on simulations
of purely theoretical datasets (e.g. Oostenbrink and
Maiwenn [6]), which have a low level of bias because they
do not include the randomness, variability and inconsist-
encies of real-world data.
In our simulations, we explored how different imput-
ation methods performed under the different mechanisms
of missing data with increasing volumes of missing data.Our findings confirm those reported previously in the the-
oretical simulation study by Oostenbrink and Maiwenn
[6]. We showed that complete case analysis performed as
well as MI MCMC for missing cost data assumed to be
MCAR. Regardless of the imputation method used, the
magnitude of bias increased as the volume of missing data
increased. However, in prospective AD studies, it is
difficult to assume or prove that data are MCAR unless
there are very small amounts of missing data. Thus, previ-
ous cost of illness studies in AD that assumed data were
MCAR and restricted analyses to study participants with
complete data (complete case analysis) [7] could have
given biased results, leading to inappropriate conclusions.
It is more realistic to assume that data are MAR (with
known factors contributing to the missing data). Our
analyses showed that MI MCMC performed well for this
mechanism of missing data. However, when missing data
were assumed to be MNAR (i.e. the trigger for missing-
ness is unknown [3]), all imputation methods performed
poorly (i.e. had high levels of bias) and this increased as
the missing data level increased to 40 %.
In reality, it is known that missing data occur for many
different reasons, especially in studies involving elderly
people [27]. One-third of patients with AD dementia
dropped out during the 18-month follow-up period of
the GERAS study because they died, were institutiona-
lised or were lost to follow-up for other reasons includ-
ing unavailability of the caregiver. Thus, there were at
least three distinct reasons for study discontinuation
and, therefore, for not having cost data. In many cost
studies, death and institutionalisation are used as end
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after death and a fixed cost for institutionalisation. For
this analysis, however, we used death and institutionali-
sation as reasons for having missing data, which enabled
the simulation of different assumptions about missing
data mechanisms.
By creating datasets that included actual volume and
patterns of reasons for discontinuation, we showed that
a single imputation method, MI MCMC, was acceptable
when the data were MCAR and/or MAR (as in the
GERAS-1 dataset). However, when some of the data
were MNAR (as in the GERAS-2 dataset) and when
using a combination of imputation methods, Scenario B
performed better than the individual approaches because
it mirrored more closely how the missing data were gen-
erated. Combination Scenario A performed better on the
GERAS-1 dataset but was similar to the MI methods.
Our analyses showed that it is important to under-
stand the reasons why patients discontinue from a study
and the reasons for missing data because it can inform
us about the most appropriate imputation methods to
use to reduce the biases due to missing data. Using a
combined approach for missing data reasons (MCAR,
MAR and MNAR) provides the opportunity to minimise
the impact of data that are MNAR and the ineffective-
ness of imputation methods to deal with this. For
example, if 30 % of data are missing overall but only
10 % of these are MNAR, then using an imputation
method that assumes the data are MAR will produce
less bias than when the proportion of MNAR is 20 %.
Kaambwa et al. [28] came to a similar conclusion in
their exploration of how different methods for analysing
missing data from an observational study were influ-
enced by using extra information obtained during data
collection about why data were missing. Thus, reasons
for missingness should be collected during prospective
studies in order to be informative in cost analyses. This
is particularly important for clinical trials, when reasons
for missing data may differ depending on the type of
treatments administered. This would be applicable not
just for AD, but also for other chronic diseases, espe-
cially those where a caregiver is also required.
We ran further simulations to consider the impact of
unmeasured confounders (see Additional file 2). For im-
putation methods that relied on knowing which factors
were associated with both missing data and costs, we
showed that performance was affected if this factor was
excluded in the imputation method (as discussed by
Spratt et al. [29]). We found that use of the correct com-
bined method could reduce this effect.
In our analyses for imputing missing data, we assumed
that the cost data were normally distributed. This is gen-
erally not a problem for large datasets like GERAS,
where you can assume the central limit theorem, whichstates that as a dataset gets larger you can assume
normality even if the data have a skewed distribution
[30]. However, bias due to missing data generally
increases with smaller datasets. The MI method used in
our analysis assumes normality. However, if working on
smaller datasets, MI methods that do not assume that
the data are normally distributed (e.g. MI predictive
mean matching regression [PMMR] and MI propensity
score) should be considered. As part of our sensitivity
analysis (see Additional file 2), MI PMMR performed
better than the MI regression method as the volume of
missing data increased, for both relative bias and
estimating the SE. The assumption of normality for the
imputation of missing data, however, does not negate
the requirement to understand the distributional proper-
ties of the cost data (with imputed values) when con-
ducting further statistical analysis.
To gain a better understanding of the relative impact
on total societal cost estimates of using different imput-
ation methods for dealing with missing cost data, we es-
timated total societal costs using different methods for
calculating informal care costs. The results showed that
decisions made about calculating the costs of caregiver
informal care time have a much bigger impact on total
societal cost estimates than decisions made about the
methods used for handling missing data, at least with
the volumes and patterns of missing data used in the
present analyses. Various methodological issues that
need to be considered when calculating informal care
costs include the instrument used to collect data on
informal care time and how informal care hours are
categorised (i.e. reliability of data capture and use of
standardised methods, such as the RUD), what informal
care hours are costed (i.e. whether or not supervision
time is included), the method used for applying costs
(e.g. opportunity versus replacement cost methods) [6],
and the valuation of unit costs (e.g. source of unit costs,
whether they are country specific). In the present study,
the different imputation methods for dealing with
missing data had minimal impact on total societal cost
estimates compared with including supervision time
(which increased total costs by 46 %) or applying differ-
ent costs for caregiver time (which changed total costs
by 24–29 %). Thus, transparency in approaches to
costing informal care will enable more accurate cost
comparisons, which will be particularly important when
assessing treatment effects.
Our analyses have several potential limitations. First,
the simulations are dependent on the method used and
the assumptions made. Simulation studies are complex
to perform and each of the many decisions that have to
be made at each stage of the process requires careful
consideration [31]. Simulation datasets can be generated
in many different ways using different factors. However,
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may impact on the outcomes. For example, cost was used
to generate the MNAR dataset. Also, some of the imput-
ation methods used MMSE and ADCS-ADL scores as fac-
tors in the model, and these factors are associated with
costs, such that costs increase as cognitive and functional
ability scores worsen [4, 8, 9, 14–16, 18, 32].
We applied a simple mechanism to generate missing cost
data based on only a small number of patient characteris-
tics. In reality, however, missing cost data are likely to be
influenced by multiple patient characteristics. We have not
explored if these methods are affected by the number of
patient factors that determine the missingness of the data.
For the purposes of this analysis, we looked at methods
used to estimate costs at a specific point in time (i.e. after
18 months of follow-up). That is, we did not apply methods
which take account of missing cost data at each visit. It
may be important to model costs throughout the follow-up
period through repeated measure models. In such circum-
stances, other imputation methods, such as last observation
carried forward or mixed-effect model repeated measures,
would need to be considered alongside the MI methods
used. However, our conclusions that bias can be reduced
when the different mechanisms of missingness can be iden-
tified are somewhat overshadowed by the effect of the deci-
sions made about calculating the costs of caregiver time.
These have a much more significant impact on societal
costs than the choice of imputation methods used.
Future work using data generated from the GERAS study
could include analyses to understand the differences by
country, to assess whether country-specific methods for
missing data need to be applied. It would be interesting to
examine whether the approach of using combinations of
imputation methods based on the different reasons for why
missing data occur can be applied to other disease area
costs. In addition, further research is needed on how to
apply these methods for handling missing data when indi-
vidual measures or items of measures are missing.
Conclusions
Missing data is a complex issue when estimating the cost
of illness, as exemplified in this analysis from the
GERAS study of patients with AD dementia. First, the
bias caused by missing data can be reduced by a better
understanding of the causes of the missing data. Where
there are different reasons for the missing data, consid-
eration should be given to the use of different imput-
ation methods. The use of single imputation techniques
can be improved by using the missingness information
to tailor imputation rules, resulting in more accurate
cost estimates. Second, in the context of other assump-
tions made for estimating costs of AD (with missing data
similar to the GERAS profile), then methods for costing
informal caregiver time have a much larger impact onthe cost estimates compared with assumptions made on
which imputation method to use. The current analysis
from the GERAS study provides important recommenda-
tions for the planning of studies involving cost outcomes,
both observational and interventional, when there may be
different reasons for dropout between cohorts. The same
analytical approach could be useful for studies of other
chronic diseases that require long-term follow-up and
have a high dropout rate. Limiting the amount of unin-
formative missing data will allow a simpler approach to
imputation, as fewer assumptions will be required.
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